Warfarin dose requirement and CYP2C9 polymorphisms -: Reply

被引：10
作者：
Aithal, GP
Day, CP
Kesteven, PJL
Daly, AK [1 ]
机构：
[1] Univ Newcastle Upon Tyne, Sch Med, Dept Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[2] Univ Newcastle Upon Tyne, Sch Med, Dept Pharmacol Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
来源：
LANCET | 1999年 / 353卷 / 9168期
关键词：
D O I：
10.1016/S0140-6736(05)77185-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1972 / 1973
页数：2
相关论文
共 4 条
[1]  
COLVIN BT, 1990, J CLIN PATHOL, V43, P177
[2]   Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms [J].
Haining, RL ;
Hunter, AP ;
Veronese, ME ;
Trager, WF ;
Rettie, AE .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1996, 333 (02) :447-458
[3]   Genetic control of anticoagulation [J].
Mannucci, PM .
LANCET, 1999, 353 (9154) :688-689
[4]   IMPAIRED (S)-WARFARIN METABOLISM CATALYZED BY THE R144C ALLELIC VARIANT OF CYP2C9 [J].
RETTIE, AE ;
WIENKERS, LC ;
GONZALEZ, FJ ;
TRAGER, WF ;
KORZEKWA, KR .
PHARMACOGENETICS, 1994, 4 (01) :39-42
1